➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Dow
Merck
Harvard Business School
McKesson

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for RAD1901

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug RAD1901?

RAD1901 is an investigational drug.

There have been 5 clinical trials for RAD1901. The most recent clinical trial was a Phase 2 trial, which was initiated on November 20th 2018.

The most common disease conditions in clinical trials are Breast Neoplasms, Hot Flashes, and [disabled in preview]. The leading clinical trial sponsors are Radius Health, Inc., Radius Pharmaceuticals, Inc., and [disabled in preview].

There are ten US patents protecting this investigational drug and forty-nine international patents.

Recent Clinical Trials for RAD1901
TitleSponsorPhase
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast CancerRadius Pharmaceuticals, Inc.Phase 3
A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerRadius Health, Inc.Phase 1
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor SymptomsRadius Health, Inc.Phase 2

See all RAD1901 clinical trials

Clinical Trial Summary for RAD1901

Top disease conditions for RAD1901
Top clinical trial sponsors for RAD1901

See all RAD1901 clinical trials

US Patents for RAD1901

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RAD1901   Start Trial Method of treating cancer using selective estrogen receptor modulators Duke University (Durham, NC)   Start Trial
RAD1901   Start Trial Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. (Research Park Triangle, NC)   Start Trial
RAD1901   Start Trial Polymorphic forms of RAD1901-2HCL Radius Pharmaceuticals, Inc. (Waltham, MA)   Start Trial
RAD1901   Start Trial Method of treating cancer using selective estrogen receptor modulators Duke University (Durham, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RAD1901

Drugname Country Document Number Estimated Expiration Related US Patent
RAD1901 Canada 2943611 2034-03-28   Start Trial
RAD1901 European Patent Office 3122426 2034-03-28   Start Trial
RAD1901 World Intellectual Property Organization (WIPO) 2015149045 2034-03-28   Start Trial
RAD1901 Argentina 110973 2037-02-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Dow
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.